● Recruiting

A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

Condition: Healthy Volunteer · Sponsor: AbbVie

PhasePhase 1

Planned participants60

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersYes

About this study

The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (2)

CenExel ACT- Anaheim Clinical Trials /ID# 281821	Anaheim, California, United States	Recruiting
Cpmi /Id# 281783	Miami, Florida, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07466550